The US Department of Health and Human Services (HHS) has introduced Operation TrialBlazer in Washington, a regulatory blueprint aimed at accelerating early-stage clinical development and narrowing the gap with China’s faster drug discovery timelines. The initiative focuses on simplifying FDA
